在前性研究中,改善了治疗尼沃卢马布治疗晚期非小细胞肺癌期间发生内分泌毒性患者的整体存活率
M Albertelli1,2, G Rossi3, E Nazzari4
1Endocrinology Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy. manuela.albertelli@unige.it.
Journal of endocrinological investigation
|April 29, 2024
概括
在接受尼沃卢马布治疗的高级非小细胞肺癌患者中,甲状腺功能低下的发展预测了更好的生存率. 监测甲状腺功能和IGF-I水平对于预测nivolumab疗效和患者结果至关重要.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 内分泌学 在内分泌学.
背景情况:
- 针对PD-1/PD-L1通路的免疫检查点抑制剂 (ICPI) 已经改变了高级非小细胞肺癌 (NSCLC) 治疗.
- 在ICPI治疗期间出现的内分泌毒性与一些研究中改善患者存活率有关.
研究的目的:
- 研究尼沃卢马布治疗晚期NSCLC和免疫相关内分泌不良事件 (irAEs) 的发生率之间的关系.
- 评估这些irAEs,特别是甲状腺功能障碍对患者生存结果的影响.
主要方法:
- 一项前性研究涉及73名先前接受治疗的先进NSCLC患者,接受尼沃卢马布单疗法.
- 通过血液样本定期监测甲状腺自身免疫,甲状腺,上腺和体轴.
- 在治疗周期中通过超声波评估甲状腺形态.
主要成果:
- 甲状腺功能障碍影响了23.4%的患者,甲状腺功能低下是显著的结果.
- 患有甲状腺功能低下症的患者的整体存活率 (OS) 与没有甲状腺功能低下症的患者相比显著改善.
- 降低的胰岛素类生长因子I (IGF-I) 水平,无论是在基线还是随访期间,都与显著降低的中位生存率有关.
结论:
- 甲状腺功能异常是NSCLC患者在nivolumab治疗中常见的irAEs.
- 甲状腺功能低下症的出现是nivolumab抗瘤功效的积极预测生物标志物.
- 低IGF-I水平可能表明尼沃卢马布治疗期间的负面预后因素,需要进一步调查.
更多相关视频
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
11.5K
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
10.6K
相关概念视频
Tumor Immunotherapy
520
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
520
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Cancer Survival Analysis
345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345
